CORIMMUN
Corimmun is a clinical drug developing company located in Martinsried near Munich, Germany, and is focused on novel therapeutics and diagnostics for heart and vascular diseases. Corimmun's activities and experiences comprise all steps from research to drug development and commercialization.
CORIMMUN
Industry:
Biotechnology Health Diagnostics
Founded:
2006-01-01
Address:
Martinsried, Bayern, Germany
Country:
Germany
Website Url:
http://www.corimmun.com
Status:
Closed
Contact:
49 89 8565 2010
Email Addresses:
[email protected]
Total Funding:
13.13 M EUR
Technology used in webpage:
Domain Not Resolving
Investors List
MIG
MIG investment in Series B - Corimmun
MIG
MIG investment in Series A - Corimmun
High-Tech Grunderfonds
High-Tech Grunderfonds investment in Series A - Corimmun
Bayern Kapital
Bayern Kapital investment in Seed Round - Corimmun
High-Tech Grunderfonds
High-Tech Grunderfonds investment in Seed Round - Corimmun
More informations about "Corimmun"
Corimmun 2025 Company Profile: Valuation, Investors ... - PitchBook
When was Corimmun founded? Corimmun was founded in 2006. Where is Corimmun headquartered? Corimmun is headquartered in Martinsried, Germany. What is the size of …See details»
Corimmun - Products, Competitors, Financials, Employees, …
Corimmun. Frequently Asked Questions (FAQ) When was Corimmun founded? Corimmun was founded in 2006. Where is Corimmun's headquarters? Corimmun's headquarters is located at …See details»
Corimmun (Exit) - HTGF
Nov 19, 2014 Corimmun entwickelt Medikamente zur Therapie von Herzinsuffizienz und Arteriosklerose. Die präklinischen Projekte COR1 und 2 zielen auf neue, entzündliche …See details»
Corimmun - 2025 Company Profile, Funding & Competitors - Tracxn
Corimmun is a clinical drug development company focused on novel therapeutics and diagnostics for heart and vascular diseases. Acquired by Janssen pharmaceuticals in June 2012. The …See details»
Corimmun GmbH Company Profile - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for Corimmun GmbH of Neuss, Nordrhein-Westfalen. Get the latest business insights from Dun & Bradstreet.See details»
Corimmun - Funding, Financials, Valuation & Investors - Crunchbase
Corimmun is a drug development company focused on therapeutics and diagnostics for heart and vascular diseases. Search Crunchbase. Start Free Trial . Chrome Extension. Solutions. …See details»
Organization | Corimmun GmbH - Purdue University
Corimmun GmbH Report issue. For profit Phase 2. Founded: Martinsried Germany ... Organization Overview. First Clinical Trial. 2009 NCT01043146. First Marketed Drug. None …See details»
Corimmun - VentureRadar
Corimmun has a unique peptide-based approach to treat auto-immune diseases. Currently COR-1, a first in class treatment of auto-immune mediated heart failure, is entering phase I in the …See details»
Corimmun - Tech Stack, Apps, Patents & Trademarks - Crunchbase
Corimmun is a drug development company focused on therapeutics and diagnostics for heart and vascular diseases.See details»
Corimmun GmbH - Company Profile and News - Bloomberg Markets
Company profile page for Corimmun GmbH including stock price, company news, executives, board members, and contact informationSee details»
Janssen Acquires Corimmun - Johnson & Johnson
Jun 28, 2012 Corimmun’s lead compound, COR-1, is a small cyclic peptide currently in early clinical development for the treatment of heart failure. COR-1 has been shown in preclinical …See details»
Corimmun GmbH Patent Filings - US Patent and Trademark Search
Patent applications and USPTO patent grants for Corimmun GmbH.The latest application filed is for "antibodies which bind to epitopes of glycoprotein vi". Company Profile. 0.1.0. Corimmun …See details»
MIG Capital
Corimmun develops peptides and human proteins for the treatment of cardiovascular diseases, especially heart failure. The main focus is dilated cardiomyopathy (DCM) and the regeneration …See details»
Janssen Acquires CorImmun - PR Newswire
Jun 28, 2012 CorImmun's lead compound, COR-1, is a small cyclic peptide currently in early clinical development for the treatment of heart failure. COR-1 has been shown in preclinical …See details»
Janssen Acquires CorImmun - Fierce Biotech
Jul 2, 2012 Janssen Acquires CorImmun NEUSS, Germany, June 28, 2012 /PRNewswire via COMTEX/ -- Janssen-Cilag GmbH (Janssen) today announced it has completed the …See details»
Janssen Buys CorImmun for Clinical-Stage Heart Failure Drug
Jun 28, 2012 CorImmun was established as a spin-out from the universities of Wuerzburg and of Tuebingen, and is focused on developing drugs for treating heart failure and atherosclerosis. …See details»
Corimmun (Exit) - HTGF
Corimmun is a drug-developing biotech company which focuses on personalized medicine in cardiovascular diseases. We concentrate on innovative peptide and biological drugs in …See details»
BioCentury - Corimmun, J&J deal
Jul 2, 2012 CorImmun's COR-1, a cyclic peptide targeting autoanti... This Edition. ARTICLE | Company News. Corimmun, J&J deal. WIR Staff. July 2, 2012 7:00 AM UTC. Johnson & …See details»
Dimeric glycoprotein VIFc(Corimmun) - Drug Targets ... - Patsnap
Abstract Glycoprotein (GP) VI (GPVI) plays a major role in thrombosis but not haemostasis, making it a promising antithrombotic target. The primary role of GPVI on the surface of …See details»
Crystadermâ„¢: An Essential Innovative Solution for Common Skin ...
5 days ago Crystadermâ„¢ contains 1% hydrogen peroxide, formulated with lipid stabilization. This advanced formulation enables the gradual release of hydrogen peroxide, ensuring …See details»